Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
| Status: | Completed |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 3/29/2017 |
| Start Date: | February 2014 |
| End Date: | December 2014 |
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Activity of NGM282 in Combination With Ursodeoxycholic Acid (UDCA) Administered for 28 Days in Patients With Primary Biliary Cirrhosis
The purpose of this study is to determine the safety, tolerability, and activity of NGM282
in patients with Primary Biliary Cirrhosis.
in patients with Primary Biliary Cirrhosis.
Inclusion Criteria:
- Males or females, between 18 and 75 years of age, inclusive
- PBC diagnosis consistent with AASLD and EASL guidelines
- Stable dose of UDCA
Exclusion Criteria:
- Chronic liver disease of a non-PBC etiology
- Evidence of clinically significant hepatic decompensation
We found this trial at
8
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials